MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2025
Intra-Cellular Therapies Cash Conversion Cycle 2011-2026 | ITCI
Annual Cash Conversion Cycle Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 257 | 261 | 69.5 | 67.3 | 86.1 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 261 | 67.3 | 148 |
Quarterly Cash Conversion Cycle Intra-Cellular Therapies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.8 | 78.3 | 77.2 | - | 71.8 | 73.1 | 75 | - | 68.9 | 65.5 | 69.1 | 65.9 | 66 | 65.7 | 70.3 | 79 | 133 | 515 | -3.43 K | - | - | - | - | - | - | - | - | 56.9 | 101 | 51.8 | 77.8 | 87.9 | 1.97 K | 37.7 | - | 91.2 | 46.1 | 48.8 | 1.13 K | 71.5 | 37.9 | 21.5 | 105 | 37.1 | 45.9 | 47.7 | 48.6 | - | 36.3 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.97 K | -3.43 K | 64.3 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 33.62 | 3.73 % | $ 2.23 B | USA |